Update: The story was updated on May 19 to include information about the underwriters exercising their overallotment option, increasing the proceed amount raised from the offering. 

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis went public on Monday in Belgium, raising about €115 million ($128 million) in proceeds. 

The company issued 8,695,652 shares of its common stock at €11.50 per share as part of its initial public offering. Its shares list on Euronext Brussels under ticker symbol "BCART." 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.